United Lab (03933) rose more than 5%, as of press time, up 5.43% to HKD 8.54, with a turnover of HKD 16.1292 million.
ZhTong Finance APP learned that United Lab (03933) rose more than 5%, as of press time, up 5.43% to HKD 8.54, with a turnover of HKD 16.1292 million.
Xiangcai Securities pointed out that due to the impact of a new round of insulin centralized procurement, different products' winning prices resulted in certain differences in the company's performance. Ganli Pharmaceutical's insulin preparation sales maintained stable growth, and the net income of the main business maintained positive growth, coupled with the impact of changes in the fair value of trading financial assets, the growth rate showed rapid growth. Tonghua Dongbao suffered a decline in revenue YoY due to the different degrees of decline in bid prices for insulin products, and customers controlling and adjusting inventory. Meanwhile, due to the provision for impairment of assets caused by the termination of clinical research projects, profits have shown a pre-loss.
Guoyuan International previously pointed out that United Lab's full-year revenue in 2023 was RMB 13.739 billion, a YoY growth of 21.2%, the net profit attributable to the parent company was RMB 2.7 billion, a YoY growth of 70.9%, and the dividend per share was RMB 0.52, a YoY growth of 108%. The bank stated that the company continues to increase R&D investment, enrich the R&D product line, and promote R&D smoothly. Core products will continue to maintain rapid growth.